New perspectives in the treatment of tobacco dependence

Monaldi Archives for Chest Disease

Volumn 60, Issue 3, 2003, Pages 179-183

  Fagerström, Karl ^a  

^a Fagerstrom Consulting   (Sweden)

Author keywords

Bupropion; Nicotine replacement; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CANNABINOID RECEPTOR ANTAGONIST; LIVER ENZYME; NICOTINE; NICOTINE DERIVATIVE; NICOTINE GUM; NICOTINE VACCINE; NICOTINIC AGENT; PLACEBO; RIMONABONT; UNCLASSIFIED DRUG; VACCINE;

CIGARETTE SMOKING; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; HUMAN; LOZENGE; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; RELAPSE; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; VACCINATION;

HUMANS; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 0345307584     PISSN: 11220643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (40)

1. Ejrup B. Heed B. Konsten att Sluta Röka. Wahlström & Widstrand 1959.
2. Cochrane group. www.dphpc.ox.ac.uk/cochrane_tobaccol
3. Jarvis MJ, Powell SR, Marsh HS et al. A meta-analysis of clinical studies confirms the effectiveness of bupropion (Zyban) in smoking cessation. Poster presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco, Savannah, GE, USA 2002.
4. Da Costa. Bupropion and Nortriptyline equally effective and psychological treatment equally effective as drug treatment. Arch Gen Psychiatry 2002; 59: 930-936.
5. Fagerström KO. Clinical treatment of tobacco dependence: The endurance of pharmacological efficacy. Clinical Psychiatry in press.
6. Jorenby DE, Leischow SJ, Mitchell AN, Rennard SI, Johnston AJ et al. A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
7. Fagerström KO. Efficacy of nicotine chewing gum. In Pomerleau O and Pomerleau C, Nicotine Replacement. Alan R Liss Inc. New York N.Y. 1988.
8. Benowitz NL. Toxicity of nicotine: Implications with regard to nicotine replacement therapy. In Pomerleau O and Pomerleau C, Nicotine Replacement. Alan R Liss Inc. New York N.Y. 1988.
9. Hurt RD, Lowel CD, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, Lauger GG, Marusic Z, Neese LW, Lundberg TG. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. JAMA 1994; 271: 595-600.
10. Sachs DPL, Benowitz NL, Bostrom AG, Hansen MD. Percent serum replacement & success of nicotine patch therapy. Presented at: 1995 ATS International Conference, Seattle, WA, USA.
11. Sweeny CT, Fant RV, Fagerström K-O, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation. CNS Drugs 2001; 15: 453-467.
12. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for nicotine dependence: A revision of the Fagerström tolerance questionnaire. British Journal of Addiction 1991; 86: 1119-1127.
13. Herrera N, Franco R, Partidas A, Fagerström K-O. Nicotine gum, 2 and 4mg, for nicotine dependence: A double-blind placebo-controlled trial within a behaviour modification support program. Chest 1995; 108: 447-451.
14. Shiffman S, Dresler CM, Hajek P, Gilburt SJA, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002; 162: 1267-1276.
15. Wallström M, Nilsson F, Hirsch J-M. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. Addiction 2000; 95: 1161-1171.
16. Sutherland G, Stapleton JA, Russell MAH et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-329.
17. Fagerström KO. Review of nicotine gum and tailoring treatment to different types of smokers. J Smoking-Related Dis 1994; 5: 179-182.
18. Pomerleau OF, Fagerström K-O, Marks JL, Tate JC, Pomerleau CS. Development and validation of a self-rating scale for positive- and negative-reinforcement smoking: The Michigan nicotine reinforcement questionnaire. In press.
19. Snyder FR, Davis FC, Henningfield JE. The tobacco withdrawal syndrome: Performance decrement assessed on a computerized test battery. Drug and Alcohol Dependence 1989; 23: 259-266.
20. Hays TJ, Hurt RD, Rigotti NA et al. Sustained release bupropion for relapse prevention after smoking cessation. Ann Intern Med 2001; 135: 423-433.
21. Tonnesen P, Paoletti P, Gustavsson G, Russel MA, Saracci R. Higher dosage nicotine patches increase one-year smoking cessation rates: Results from the European CEASE trial. Eur Respir J 1999; 13: 238-246.
22. Bolliger CT, Zellweger JP, Danielsson T, Biljon X, Robidou A et al. Influence of long term smoking reduction on health risk markers and quality of life. Nicotine & Tobacco Research. In press.
23. Hurt R, Croghan G, Wolter T, Croghan I, Offord K et al. Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine & Tobacco Research 2000; 2: 327-336.
24. Stratton K, Shetty P, Wallace R et al. Clearing the Smoke. Assessing the Science Base for Tobacco Harm Reduction. Institute of Medicine. National Academy Press. Washington D.C. USA 2001.
25. Bolliger C, Zellweger P, Danielsson T, Biljon X, Robidou A. et al. 2000. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety. British Medical J 321: 329-333.
26. Haustein K-O, Batra A, Landfeldt B, Westin Å. The effect of short-term or long-term reduction on smoking cessation; Results from a placebo controlled smoking reduction study with the nicotine gum. Poster at 4th Annual Meeting of the Society for Research on Nicotine and Tobacco. Santander, Spain, Oct. 3-5, 2002.
27. Kralikova E, Kozak J, Rasmussen T. The clinical benefits of NRT-supported smoking reduction. Nicotine and Tobacco Research 2002; 4: 243.
28. Rennard SI, Glover E, Leischow S et al. Efficacy of nicotine inhaler in smoking reduction. Nicotine and Tobacco Research 2002; 4: 380.
29. Wennike PJ, Bremann L, Tonnesen P. Does smoking cessation/reduction improve asthma regulation. Poster at the Annual Meeting of the European Respiratory Society, Berlin, Sept. 20-24, 2001.
30. Etter J-F, Laszlo E, Zellweger J-P, Perrot C, Perneger T. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. Journal of Clinical Psychopharmacology 2002; 22: 1-9.
31. Carpenter MJ, Hughes JR, Keely JP. Smoking reduction and cessation. Effects of smoking reduction on later cessation: A pilot experimental study. Submitted paper.
32. Hatsukami D, Rennard S, Malcolm R, Jamerson BD, Dozier G, Patel MK. A multicentre study examining the effects of Zyban (Bupropion SR) vs placebo an aid to smoking reduction leading to cessation among smokers unwilling or unable to quit smoking. Nicotine and Tobacco Research 2002; 4: 241.
33. Tonnesen P, Wennike P, Pisinger C et al. Smoking cessation and smoking reduction in asthmatics. Poster at 4th Annual Meeting of the Society for Research on Nicotine and Tobacco. Santander, Spain, Oct. 3-5, 2002.
34. Bonese KF, Wainer BH, Fitch FW et al. Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 1974; 252: 708-10.
35. Malin DH, Lake JR, Lin A et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68 (1): 87-92.
36. De Villers S, Lindblom N, Kalanyanov G et al. Active immunization against nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002; 69: 247-253.
37. Lindblom N, De Villers S, Kalaynov G et al. Active immunization against nicotine prevents reinstatement of nicotine-seeking behaviour in rats. Respiration 2002; 69: 254-260.
38. Hieda Y, Keyler DE, Vandevoort JT, Kane JK, Ross CA, Raphael DE. Active immunization alters the plasma nicotine concentration in rats. Pharmacol Exp Ther 1997; 283: 1076-1081.
39. Lindmayer K, Horwith G, Fattom A. Results of a phase I, double-blind, placebo controlled safety and immunogenicity trial of NicVax, a conjugated nicotine vaccine. Poster at 4th Annual Meeting of the Society for Research on Nicotine and Tobacco. Santander, Spain, Oct. 3-5, 2002.
40. Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology & Therapeutics 2000; 68: 35-43.